Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics (NASDAQ:SNSE) announced a virtual Key Opinion Leader (KOL) event scheduled for October 20, 2025, at 8:00 AM ET. The event will feature Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START San Antonio, who will discuss immunotherapy-resistant solid tumors.
The presentation will include updates on Phase 2 study plans and complete data from the Phase 1/2 dose expansion cohort for Solnerstotug (formerly SNS-101), their conditionally active monoclonal antibody targeting VISTA in PD-(L)1 resistant tumors. The data will also be presented at ESMO on October 17th.
Sensei Biotherapeutics (NASDAQ:SNSE), a clinical stage biotech company developing next-generation cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO John Celebi will conduct one-on-one investor meetings on September 8, 2025. The company's on-demand corporate presentation will be available starting September 5, 2025, at 7:00 a.m. ET. Investors can access the webcast replay in the Investors section of Sensei's website for approximately 90 days after the event.
Sensei Biotherapeutics (NASDAQ:SNSE) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead candidate solnerstotug showed promising results in its Phase 1/2 trial, demonstrating a favorable safety profile in combination with cemiplimab. The study included 64 patients in the dose expansion cohort, with 41 patients having prior PD-(L)1 resistance.
Financial highlights include cash position of $28.6 million as of June 30, 2025, expected to fund operations into Q2 2026. The company reported a reduced net loss of $4.9 million compared to $7.1 million in Q2 2024, with decreased R&D expenses of $2.5 million and G&A expenses of $2.7 million.
Full data from the Phase 1/2 dose expansion cohort is expected by year-end 2025, with upcoming presentation at ESMO Congress 2025 in October.
Sensei Biotherapeutics (NASDAQ: SNSE) has announced an upcoming presentation of clinical data at the ESMO Congress 2025 in Berlin, Germany. The presentation will focus on results from the Phase 1 dose expansion cohort studying solnerstotug, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab).
The study specifically examines patients with advanced solid tumors resistant to prior PD-(L)1 therapy. Dr. Kyriakos Papadopoulos from START, San Antonio will present the findings on October 17, 2025 during a mini oral session.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.
Sensei Biotherapeutics (NASDAQ: SNSE) reported its full year 2024 financial results and clinical progress for solnerstotug, their conditionally active antibody targeting VISTA. Key clinical highlights include:
In the Phase 1/2 dose expansion study, among 21 evaluable PD-(L)1 resistant tumor patients, the combination therapy showed 14% overall response rate (3x higher than historical rates) and 62% disease control rate. The study achieved target enrollment of 60 patients, with full expansion data expected by year-end 2025.
Financial results show:
- Cash position: $41.3M as of December 31, 2024
- R&D expenses: $18.6M (vs $18.3M in 2023)
- G&A expenses: $13.0M (vs $18.8M in 2023)
- Net loss: $30.2M (vs $34.1M in 2023)
The company expects its current cash runway to extend into Q2 2026.
Sensei Biotherapeutics (NASDAQ: SNSE) has reported promising preliminary results from its Phase 1/2 trial of solnerstotug, a conditionally active antibody targeting VISTA. The drug showed significant clinical activity in PD-(L)1 resistant tumors, achieving a 14% overall response rate - nearly triple the historical rechallenge rates of ≤5%.
Key findings include:
- One durable complete response in Merkel Cell Carcinoma (MCC)
- Two partial responses in MCC and MSI-H Colorectal Cancer patients
- 62% disease control rate among 21 evaluable PD-(L)1 resistant patients
- All patients with tumor shrinkage remain on treatment
The drug demonstrated favorable safety with no dose-limiting toxicities, mostly Grade 1-2 adverse events, and only 7% cases of mild cytokine release syndrome. Subject to capital raising, Sensei plans to initiate Phase 2 studies in Q1 2026.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company's President and CEO, John Celebi, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 10:40 a.m. ET.
Interested parties can access the presentation webcast through the Investors section of Sensei's website. The replay will remain available for approximately 90 days after the event, and registration for the webcast is currently open.